Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks

• Authors: STAUBACH Petra; TACHDJIAN Raffi; LI H. Henry; HAKL Roman; AYGÖREN-PÜRSÜN Emel; WIEMAN Lolis; JOHN-PHILIP Lawo; CRAIG Timothy J.
• Year of publication: 2024
• Type: Article in Periodical
• Magazine / Source: Clinical & Experimental Allergy
• MU Faculty or unit: Faculty of Medicine
• web: https://onlinelibrary.wiley.com/journal/13652222
• Doi: https://doi.org/10.1111/cea.14568
• Keywords: hereditary angioedema; garadacimab; attack prevention; treatment timing; clinical study
• Description: Hereditary angioedema (HAE) is a rare, autosomal dominant disease characterised by recurrent, unpredictable, painful, debilitating and potentially life-threatening attacks. HAE imparts a substantial disease burden that impacts daily activities and extends beyond symptoms directly attributable to HAE attacks, encompassing mental health (anxiety and depression) and psychosocial impacts associated with unpredictable attack recurrence.